Yoo M , Khaled M , Gibbs KM , Kim J , Kowalewski B , Dierks T , Schachner M .

	Figure 1. Thermostability of ARSB and ChaseABC.Stock solutions of each enzyme were incubated at 37°C/pH 6.8 for up to 125 hours. At the indicated time points aliquots were diluted into pre-warmed assay buffer (pH 8.0 for ChaseABC, pH 5.6 for ARSB) and subjected to activity determination (see Methods). Asterisks indicate significant differences between the groups *p<0.001 as assessed by t-Test. Data represent means ± SEM (n = 4).
	Figure 2. Chondroitin 4-O-sulfate (C4S) immunoreactivity is reduced at five days after ARSB injection after moderate compression-injury.Immediately after spinal cord injury, one µl of ARSB (10 U/ml) was injected at the injury site (arrow) and 0.5 mm rostral and caudal to this site (arrowheads). After 5 days, the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence using an antibody specific for C4S. C4S immunoreactivity is higher at the injury site in the buffer treated control mice (A) versus ARSB treated mice (B). (C) and (D) are higher magnifications of the insets in (A) and (B), respectively. Diamidino-phenylindole (DAPI, blue) was used for nuclear staining and merged with C4S immunoreactivity (C,D). Arrows and arrowheads indicate the injury site and injection sites, respectively.
	Figure 3. C4S immunoreactivity is reduced at 9 weeks after enzyme injection in severe compression injury.Immediately after spinal cord injury, one µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site. After 9 weeks, the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence using an antibody specific for C4S. C4S immunoreactivity is more intense at the injury site in the buffer treated control mice (A) versus the ChaseABC (B) and ARSB (C) treated mice. Immunoreactivities of the entire images were quantified above threshold using Image J software (D). Mean fluorescence intensities of the area at 0.4 mm equidistant rostral and caudal to the center of the injury site show significantly less C4S immunoreactivity in ChaseABC and ARSB treated mice versus buffer treated control mice. Reduction of immunoreactivity is not significantly different between applications of ChaseABC versus ARSB. Arrows indicate the injury site. Asterisks indicate significant differences between the groups *p<0.05 and **p<0.01 as assessed by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM (n = 4 mice).
	Figure 4. C4S and C6S immunoreactivities are reduced at 6 and 9 weeks after ARSB and ChaseABC treatment.Immediately after moderate (A,B) and severe (C–E) spinal cord injury, one µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site. After 6 (A,B) and 9 weeks (C–E), the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence using the CS56 antibody reacting with C4S and C6S. Immunoreactivity is more intense at the injury site in the buffer treated control mice (A,C) versus the ChaseABC (D) and ARSB (B,E) treated mice. Immunoreactivities of the entire images were quantified above threshold using Image J software (F). Mean fluorescence intensities of the area at 0.4 mm equidistant rostral and caudal to the center of the injury site show significantly less expression of CSs in ChaseABC and ARSB treated mice versus buffer treated control mice. Reduction of immunoreactivity is not significantly different between applications of ChaseABC versus ARSB. Arrows indicate the injury site. Asterisks indicate significant differences between the groups *p<0.05 (ARSB) and **p<0.01 (ChaseABC) as assessed by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM, (n = 3 mice).
	Figure 5. Functional recovery of ChaseABC or ARSB treated mice after moderate (A) and severe (B) compression.One µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site. The Basso Mouse Scale for analysis of locomotor activity was used to score functional recovery up to 6 (A) and 9 (B) weeks after moderate and severe spinal cord injury (SCI), respectively. Asterisks indicate significant differences between the enzyme treated groups versus the buffer treated control group at the same time points (*p<0.05, **p<0.01). No significant difference is detectable between the ChaseABC and ARSB treated groups by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM. Number of mice are indicated in brackets.
	Figure 6. GFAP immunoreactivity is not different at 6 or 9 weeks after enzyme treatment.One µl of the ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site after moderate and severe compression injury. After 6 (A,B) and 9 weeks (C–E), the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence for glial fibrillary acidic protein (GFAP). Photomicrographs show GFAP immunoreactivity at the injury site in the buffer treated control mice (A,C) versus ChaseABC (D) and ARSB (B,E) treated mice. Immunoreactive areas were quantified above threshold using Image J software (F). Mean fluorescence intensities of the area at 0.4 mm equidistant rostral and caudal to the center of the injury site are similar in all groups. Arrows indicate the injury site. One-way ANOVA followed by Tukey’s post-hoc analysis indicates no difference between the groups (p>0.9). Data represent means ± SEM (n = 3 mice).
	Figure 7. 5-HT immunoreactive axons are more abundant 9 weeks after enzyme treatment than in control mice.One µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site in mice with severe compression injury. After 9 weeks, the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence. Double immunostaining for serotonin (5-HT) and neurofilament-M (NF-M) shows higher immunoreactivities caudal injury site in the ChaseABC (D,E,F) and ARSB (G,H,I) treated mice versus buffer treated control mice (A,B,C). (A,D,G) Immunostainings for 5-HT and (B,E,H) NF-M, and (C,F,I) merged for 5-HT with NF-M. 5-HT immunoreactive axons are seen beyond the injury site in the ChaseABC and ARSB injected mice. Immunoreactive areas were quantified above threshold using Image J software (J). Mean fluorescence intensity of the area between the injury site and 1 mm caudal to it is significantly higher in ChaseABC treated versus buffer treated control mice. Asterisk indicates significant differences between the groups *p<0.05 by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM, (n = 5 mice).
	Figure 8. Tyrosine hydroxylase (TH) immunoreactive axons are more abundant 9 weeks after enzyme treatment than in control mice.One µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal of this site in mice with severe compression injury. After 9 weeks, the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence. Double immunostaining for TH and neurofilament-M (NF-M) shows higher immunoreactivities caudal to the injury site in the ChaseABC (D,E,F) and ARSB (G,H,I) treated mice versus the buffer treated control mice (A,B,C). (A,D,G) Immunostainings for TH and (B,E,H) NF-M, and (C,F,I) merged for TH with NF-M. Immunoreactive areas were quantified above threshold using Image J software (J). Mean fluorescence intensity of the area between the injury site and 1 mm caudal to it shows significantly higher immunofluorescence intensity in ARSB versus buffer treated control and ChaseABC treated mice. Asterisks indicate significant differences between the groups *p<0.05 and **p<0.01 as assessed by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM, (n = 4 mice).
	Figure 9. Iba1 immunoreactive microglia/macrophages are more abundant 9 weeks after ChaseABC treatment than in control mice.One µl ChaseABC (10 U/ml), ARSB (10 U/ml) or buffer was injected at the injury site and 0.5 mm rostral and caudal to this site in mice after severe compression. After 9 weeks, the mice were perfused, and sagittal spinal cord sections were analyzed by immunofluorescence. Immunoreactivity for Iba1 is less intense at the injury site in the buffer treated control mice (A) versus ChaseABC (B) or ARSB (C) treated mice. (D) (E) and (F) are higher magnifications of the insets in (A) (B) and (C), respectively, showing more microglia/macrophages with activated, amoeboid morphology in the area between the injury site and 1 mm caudal to it of mice treated with ChaseABC (E) or ARSB (F) versus the buffer treated control mice (D). Immunoreactive areas were quantified above threshold using Image J software (G). Mean fluorescence intensities at 0.4 mm equidistant rostral and caudal to the center of the injury site shows significantly higher immunoreactivity for Iba1 in ChaseABC treated mice versus buffer treated control mice. Arrows indicate the injury site. Diamidino-phenylindole (DAPI, blue) was used for nuclear staining and merged with Iba1 immunostaining (D,E,F). Asterisk indicates a significant difference between the groups *p<0.05 as assessed by one-way ANOVA followed by Tukey’s post-hoc analysis. Data represent means ± SEM, (n = 3 mice).

Alilain, Functional regeneration of respiratory pathways after spinal cord injury. 2011, Pubmed

Alilain, Functional regeneration of respiratory pathways after spinal cord injury. 2011, Pubmed
Anson, Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. 1992, Pubmed
Apostolova, Tenascin-R restricts posttraumatic remodeling of motoneuron innervation and functional recovery after spinal cord injury in adult mice. 2006, Pubmed
Asher, Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. 2000, Pubmed
Basso, Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. 2006, Pubmed
Bovolenta, Neurite outgrowth over resting and reactive astrocytes. 1991, Pubmed
Bradbury, Chondroitinase ABC promotes functional recovery after spinal cord injury. 2002, Pubmed
Bradbury, Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. 2011, Pubmed
Brittis, Chondroitin sulfate as a regulator of neuronal patterning in the retina. 1992, Pubmed
Butterfield, Identification and sequence composition characterization of chondroitin sulfate-binding peptides through peptide array screening. 2010, Pubmed
Butterfield, Chondroitin sulfate-binding peptides block chondroitin 6-sulfate inhibition of cortical neurite growth. 2010, Pubmed
Caggiano, Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord. 2005, Pubmed
Carulli, Upregulation of aggrecan, link protein 1, and hyaluronan synthases during formation of perineuronal nets in the rat cerebellum. 2007, Pubmed
Cavalcante, Sulfated proteoglycans as modulators of neuronal migration and axonal decussation in the developing midbrain. 2003, Pubmed
Curtis, Up-regulation of GAP-43 and growth of axons in rat spinal cord after compression injury. 1993, Pubmed
Deepa, Composition of perineuronal net extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. 2006, Pubmed
Deepa, Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes. 2007, Pubmed
Dierks, Conversion of cysteine to formylglycine in eukaryotic sulfatases occurs by a common mechanism in the endoplasmic reticulum. 1998, Pubmed
Fawcett, The glial scar and central nervous system repair. 1999, Pubmed
Fehlings, Repair of the chronically injured human spinal cord. 2008, Pubmed
Fitch, Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. 1999, Pubmed
Fitch, CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. 2008, Pubmed
Fouad, Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. 2005, Pubmed
García-Alías, Therapeutic time window for the application of chondroitinase ABC after spinal cord injury. 2008, Pubmed
Gilbert, CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension. 2005, Pubmed
Giulian, Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. 1990, Pubmed
Gorham, Arylsulphatase B, an exo-sulphatase for chondroitin 4-sulphate tetrasaccharide. 1978, Pubmed
Hamai, Two distinct chondroitin sulfate ABC lyases. An endoeliminase yielding tetrasaccharides and an exoeliminase preferentially acting on oligosaccharides. 1997, Pubmed
Harmatz, Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). 2004, Pubmed
Harmatz, Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. 2005, Pubmed
Hawthorne, The unusual response of serotonergic neurons after CNS Injury: lack of axonal dieback and enhanced sprouting within the inhibitory environment of the glial scar. 2011, Pubmed
Huang, Chondroitinase ABC promotes axonal re-growth and behavior recovery in spinal cord injury. 2006, Pubmed
Huang, The effects of arterial blood gas values on lesion volumes in a graded rat spinal cord contusion model. 1994, Pubmed
Iseda, Single, high-dose intraspinal injection of chondroitinase reduces glycosaminoglycans in injured spinal cord and promotes corticospinal axonal regrowth after hemisection but not contusion. 2008, Pubmed
Jones, The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. 2003, Pubmed
Karimi-Abdolrezaee, Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. 2010, Pubmed
Karumbaiah, Targeted downregulation of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase significantly mitigates chondroitin sulfate proteoglycan-mediated inhibition. 2011, Pubmed
Kigerl, Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. 2009, Pubmed
Kim, Degradation of chondroitin sulfate proteoglycans potentiates transplant-mediated axonal remodeling and functional recovery after spinal cord injury in adult rats. 2006, Pubmed
Knaust, Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A. 1998, Pubmed
Koshiishi, Enzymatic method for the simultaneous determination of hyaluronan and chondroitin sulfates using high-performance liquid chromatography. 1998, Pubmed
Lamanna, Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. 2008, Pubmed
Lee, Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. 2010, Pubmed
Li, Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. 2007, Pubmed
Lin, 6-Sulphated chondroitins have a positive influence on axonal regeneration. 2011, Pubmed
Lin, Chondroitinase ABC has a long-lasting effect on chondroitin sulphate glycosaminoglycan content in the injured rat brain. 2008, Pubmed
Liu, Upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth. 2006, Pubmed
McKeon, The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. 1999, Pubmed
McKeon, Injury-induced proteoglycans inhibit the potential for laminin-mediated axon growth on astrocytic scars. 1995, Pubmed
Mitsunaga-Nakatsubo, Cell-surface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers. 2009, Pubmed
Morgenstern, Chondroitin sulphate proteoglycans in the CNS injury response. 2002, Pubmed
Mukhopadhyay, A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. 1994, Pubmed
Muñoz-Rojas, Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. 2010, Pubmed
Pizzorusso, Reactivation of ocular dominance plasticity in the adult visual cortex. 2002, Pubmed
Popovich, Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. 1999, Pubmed
Porter, Metachromatic leukodystrophy: arylsulfatase-A deficiency in skin fibroblast cultures. 1969, Pubmed
Prabhakar, Recombinant expression, purification, and biochemical characterization of chondroitinase ABC II from Proteus vulgaris. 2009, Pubmed
Prabhakar, Chondroitinase ABC I from Proteus vulgaris: cloning, recombinant expression and active site identification. 2005, Pubmed
Properzi, Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia. 2005, Pubmed
Raineteau, Plasticity of motor systems after incomplete spinal cord injury. 2001, Pubmed
Rolls, The bright side of the glial scar in CNS repair. 2009, Pubmed
Schachtrup, Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. 2010, Pubmed
Shechter, The glial scar-monocyte interplay: a pivotal resolution phase in spinal cord repair. 2011, Pubmed
Silver, Inhibitory molecules in development and regeneration. 1994, Pubmed
Skidmore, Disaccharide compositional analysis of heparan sulfate and heparin polysaccharides using UV or high-sensitivity fluorescence (BODIPY) detection. 2010, Pubmed
Steward, False resurrections: distinguishing regenerated from spared axons in the injured central nervous system. 2003, Pubmed
Susarla, Smad proteins differentially regulate transforming growth factor-β-mediated induction of chondroitin sulfate proteoglycans. 2011, Pubmed
Tester, Effect of body temperature on chondroitinase ABC's ability to cleave chondroitin sulfate glycosaminoglycans. 2007, Pubmed
Vink, Effects of traumatic brain injury on cerebral high-energy phosphates and pH: a 31P magnetic resonance spectroscopy study. 1987, Pubmed
Wang, Chondroitin-4-sulfation negatively regulates axonal guidance and growth. 2008, Pubmed
Wasserman, Arylsulfatase B of human lung. Isolation, characterization, and interaction with slow-reacting substance of anaphylaxis. 1976, Pubmed
Wilson, Chondroitin sulfate proteoglycan expression pattern in hippocampal development: potential regulation of axon tract formation. 2000, Pubmed
Xiong, Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. 2004, Pubmed
Yi, Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice. 2012, Pubmed
Yick, Axonal regeneration of Clarke's neurons beyond the spinal cord injury scar after treatment with chondroitinase ABC. 2003, Pubmed